Arna Pharma and Slate Run Pharmaceuticals have finalized a significant joint venture (JV), establishing a new specialized pharmaceutical entity poised…
Read More
Biotech Bi-Weekly: Pioneering Product Launches, Strategic Alliances, and Significant Financial Movements Shape the Industry
The dynamic landscape of biotechnology continues to evolve at an accelerated pace, marked by a flurry of innovative product launches,…
Read More
Pharma Manufacturing Facility Sales to Outsourcers Signal Growing Industry Demand for Strategic Flexibility
A notable surge in the acquisition of pharmaceutical manufacturing facilities by contract development and manufacturing organizations (CDMOs) has illuminated a…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read More
Labcorp and Children’s Hospital of Philadelphia Forge Strategic Alliance to Revolutionize Pediatric Diagnostics and National Access
Labcorp, a leading global life sciences company, and the Children’s Hospital of Philadelphia (CHOP), a globally recognized leader in pediatric…
Read More
Sai Life Sciences Hosts Landmark Biotech Pitch Day 2026, Spotlighting Innovative Early-Stage Therapies and Fostering Strategic Collaborations
Sai Life Sciences, a leading global contract research, development, and manufacturing organization (CRDMO), recently convened its highly anticipated Biotech Pitch…
Read More
Saudi Arabia Ascends as a Premier Middle Eastern Hub for Clinical Trials Fueled by Strategic Investment and Infrastructure Development
Saudi Arabia is rapidly solidifying its position as the preeminent growth market for clinical trials within the Middle East, a…
Read More
Novartis Navigates Generics Storm in Q1, Eyes Robust Future Fueled by Strategic Acquisitions and Pipeline Advancements
Novartis reported a challenging first quarter for 2026, with profits experiencing a significant downturn primarily due to the intensified impact…
Read More
The Surge in Oncology Innovation Fuels Strategic Investment in HPAPI and ADC Manufacturing Capabilities
The accelerating demand for highly potent active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates (ADCs) is compelling contract development and manufacturing…
Read More
Eli Lilly Acquires Ajax Therapeutics for Up to $2.3 Billion in Strategic Move to Bolster Oncology Pipeline
Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
